Global Diabetic Gastroparesis Treatment Market Overview 2024, Forecast To 2033
8 Mar, 2024
The diabetic gastroparesis treatment market is poised for growth, rising from $3.68 billion in 2023 to $3.86 billion in 2024, at a 5.0% CAGR. By 2028, it's projected to reach $4.73 billion, driven by personalized therapies and increasing diabetic population, with trends emphasizing technological innovations and symptom management.
Global Diabetic Gastroparesis Treatment Market Key Driver
The diabetic gastroparesis treatment market is projected to grow with the increasing prevalence of diabetes. The British Diabetic Association reports a significant number of individuals living with diabetes in the UK, driving demand for gastroparesis treatment to manage associated complications.
Get A Free Sample Of The Global Diabetic Gastroparesis Treatment Market ReportGlobal Diabetic Gastroparesis Treatment Market Segments
The diabetic gastroparesis treatment market covered in this report is segmented –
1) Treatment:Medication, Surgery
2) Route Of Administration:Oral, Injectables
3) Indication:Compensated Gastroparesis, Gastric Failure
4) Distribution Channel:Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
5) End User:Hospitals, Homecare, Specialty Clinics, Other End Users
By Geography: The countries covered in the diabetic gastroparesis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
North America was the largest region in the diabetic gastroparesis treatment market in 2023, and is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic gastroparesis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Diabetic Gastroparesis Treatment Industry Players
Cardinal Health Inc.; Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Ipca Laboratories Ltd.; Abbott Laboratories; GlaxoSmithKline plc; AstraZeneca plc; Medtronics plc; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Kimberly-Clark Corporation; Teva Pharmaceutical Industries Ltd.; Janssen Global Services LLC; Boston Scientific Corporation; Fresenius Kabi AG; Bausch Health Companies Inc.; Allergan Inc.; Salix Pharmaceuticals Inc.; Ironwood Pharmaceuticals Inc.; Wockhardt Ltd.; ANI Pharmaceuticals Inc.; Endologic LLC; Vanda Pharmaceuticals Inc.; Rhythm Pharmaceuticals Inc.; Theravance Biopharma Inc.; Neurogastrx Inc.; Evoke Pharma Inc.; CinRx Pharma LLC
Get The Full Global Diabetic Gastroparesis Treatment Market Report
Diabetic Gastroparesis Treatment Market Overview
Diabetic gastroparesis is a condition in which high blood glucose levels damage the stomach muscles and nerves, leading to delayed gastric emptying and other symptoms. Diabetic gastroparesis treatment refers to the medical interventions and management strategies employed to alleviate symptoms and improve the overall well-being of individuals with this condition. The treatment approach may involve several interventions to address delayed stomach emptying and associated gastrointestinal symptoms.